Navigation Links
Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
Date:9/8/2010

CARLSBAD, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Stifel Nicolaus' 2010 Healthcare Conference on Thursday, September 16, 2010 at 8:35 a.m. ET at The Four Seasons Hotel in Boston, MA.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 23 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
2. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
3. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
6. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
7. Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
8. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
11. Pfizer to Acquire FoldRx Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... OSWEGO, Ore. , Dec. 5, 2016   ... the BioInsight clinical study. The study evaluates the safety ... insertion procedure in an office setting. BioMonitor ... ® technology that is placed underneath a patient,s ... fibrillation and syncope (fainting). Atrial fibrillation is a leading ...
(Date:12/5/2016)... --  TrainerMD , the first HIPAA compliant software collaboration platform for ... Styku . Styku, a California -based ... users world-class, real-time 3D body scanning and analysis. Together with its ... hear and feel their health like never before. ... , , ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) ... 125 for their industry leading training methods that engage their associates and link ... the global elite in employer-sponsored training and development programs. , “The 2017 Training ...
(Date:12/5/2016)... (PRWEB) , ... December 06, 2016 , ... For many ... Lithuanian poetry , both thick and thin. The beauty of the Lithuanian language ... Trafford Publishing). , In this poetry book, Zubinas lyrically explores all aspects of a ...
(Date:12/5/2016)... ... 2016 , ... “Epilepsy Awareness,” which can be found at ... conversation about epilepsy, bearing down on the social stigma and lack of public ... epilepsy within their lifetime. With such a large percentage of people affected, it’s ...
(Date:12/5/2016)... ... ... BSI and Brenntag Canada have been appointed by Chr. Hansen as their ... fruits and beverage colorants effective November 1, 2016. , “The ... product portfolio,” said Steve Brauer, President of Brenntag Specialties, Inc. “Representing Chr. Hansen will ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ("GPP") portfolio company, today announced it has acquired the assets of Frankfurt, ... previously a subsidiary of Chiltern International and focuses on clinical trial drug ...
Breaking Medicine News(10 mins):